open access

Vol 27, No 6 (2020)
Original Article
Submitted: 2018-03-14
Accepted: 2018-05-04
Published online: 2018-06-14
Get Citation

The atherogenic index of plasma and its impact on recanalization of chronic total occlusion

Jan-Erik Guelker1, Alexander Bufe1, Christian Blockhaus1, Knut Kroeger1, Thomas Rock1, Ibrahim Akin2, Michael Behnes2, Kambis Mashayekhi3
·
Pubmed: 29924378
·
Cardiol J 2020;27(6):756-761.
Affiliations
  1. Helios Clinic Krefeld, Lutherplatz 40, 47805 Krefeld, Germany
  2. 1st Medical Department, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Germany
  3. Division of Cardiology and Angiology II, University Heart Center Freiburg • Bad Krozingen,

open access

Vol 27, No 6 (2020)
Original articles — Clinical cardiology
Submitted: 2018-03-14
Accepted: 2018-05-04
Published online: 2018-06-14

Abstract

Background: The plasma-derived atherogenic index (AIP) is associated with an increasing risk for cardiovascular diseases. Whether an increased AIP may predict the complexity of percutaneous coronary intervention (PCI) of chronic total occlusion (CTO), according to available research, has never been investigated before.

Methods: Three hundred seventeen patients were included prospectively and treated with PCI for at least one CTO between 2012 and 2017. High-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) plasma levels were measured 24 h before PCI. All patients were stratified into tertiles of AIP (defined as 0.11, 0.11–0.21, > 0.21) based on their TG/HDL-C (AIP) levels.

Results: Mean AIP of all patients undergoing CTO-PCI was 0.53 ± 0.29. The majority of patients were male (82.6%), and mean age was 61 ± 10.4 years. Increased AIP > 0.21 was associated with longer occlusion length (statistical trend p = 0.082) and stent routes (p = 0.022) and with a higher number of implanted stents (n > 4) (statistical trend p = 0.072). Success rates were similar in all AIP categories (p = 0.461). In-hospital PCI-related complications were rare and not statistically different (p = 0.852).

Conclusions: This study demonstrates for the first time that an increased AIP may predict the complexity of CTO-PCI and additionally may help to improve planning and quality of CTO-PCI.

Abstract

Background: The plasma-derived atherogenic index (AIP) is associated with an increasing risk for cardiovascular diseases. Whether an increased AIP may predict the complexity of percutaneous coronary intervention (PCI) of chronic total occlusion (CTO), according to available research, has never been investigated before.

Methods: Three hundred seventeen patients were included prospectively and treated with PCI for at least one CTO between 2012 and 2017. High-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) plasma levels were measured 24 h before PCI. All patients were stratified into tertiles of AIP (defined as 0.11, 0.11–0.21, > 0.21) based on their TG/HDL-C (AIP) levels.

Results: Mean AIP of all patients undergoing CTO-PCI was 0.53 ± 0.29. The majority of patients were male (82.6%), and mean age was 61 ± 10.4 years. Increased AIP > 0.21 was associated with longer occlusion length (statistical trend p = 0.082) and stent routes (p = 0.022) and with a higher number of implanted stents (n > 4) (statistical trend p = 0.072). Success rates were similar in all AIP categories (p = 0.461). In-hospital PCI-related complications were rare and not statistically different (p = 0.852).

Conclusions: This study demonstrates for the first time that an increased AIP may predict the complexity of CTO-PCI and additionally may help to improve planning and quality of CTO-PCI.

Get Citation

Keywords

atherogenic index, chronic total occlusion, coronary artery disease, percutaneous coronary intervention

About this article
Title

The atherogenic index of plasma and its impact on recanalization of chronic total occlusion

Journal

Cardiology Journal

Issue

Vol 27, No 6 (2020)

Article type

Original Article

Pages

756-761

Published online

2018-06-14

Page views

3536

Article views/downloads

1614

DOI

10.5603/CJ.a2018.0064

Pubmed

29924378

Bibliographic record

Cardiol J 2020;27(6):756-761.

Keywords

atherogenic index
chronic total occlusion
coronary artery disease
percutaneous coronary intervention

Authors

Jan-Erik Guelker
Alexander Bufe
Christian Blockhaus
Knut Kroeger
Thomas Rock
Ibrahim Akin
Michael Behnes
Kambis Mashayekhi

References (24)
  1. Fefer P, Knudtson ML, Cheema AN, et al. Current perspectives on coronary chronic total occlusions: the Canadian Multicenter Chronic Total Occlusions Registry. J Am Coll Cardiol. 2012; 59(11): 991–997.
  2. Tomasello SD, Boukhris M, Giubilato S, et al. Management strategies in patients affected by chronic total occlusions: results from the Italian Registry of Chronic Total Occlusions. Eur Heart J. 2015; 36(45): 3189–3198.
  3. Bufe A, Haltern G, Dinh W, et al. Recanalisation of coronary chronic total occlusions with new techniques including the retrograde approach via collaterals. Neth Heart J. 2011; 19(4): 162–167.
  4. Galassi AR, Tomasello SD, Reifart N, et al. In-hospital outcomes of percutaneous coronary intervention in patients with chronic total occlusion: insights from the ERCTO (European Registry of Chronic Total Occlusion) registry. EuroIntervention. 2011; 7(4): 472–479.
  5. Stähli BE, Gebhard C, Gick M, et al. Impact of body mass index on long-term mortality in women and men undergoing percutaneous coronary intervention for chronic total occlusion. Int J Cardiol. 2016; 224: 305–309.
  6. Lemieux I, Lamarche B, Couillard C, et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med. 2001; 161(22): 2685–2692.
  7. Lemos da Luz P, Favarato D, Faria-Neto Junior JR, et al. High ratio of triglycerides to hdl-cholesterol predicts extensive coronary disease. Clinics. 2008; 63(4).
  8. Khazaál MS. Atherogenic Index of Plasma (AIP) as a parameter in predicting cardiovascular risk in males compared to the conventional dyslipidemic indices (cholesterol ratios). Karbala J Med. 2013; 6(1): 1506–11.
  9. Morino Y, Abe M, Morimoto T, et al. J-CTO Registry Investigators. Predicting successful guidewire crossing through chronic total occlusion of native coronary lesions within 30 minutes: the J-CTO (Multicenter CTO Registry in Japan) score as a difficulty grading and time assessment tool. JACC Cardiovasc Interv. 2011; 4(2): 213–221.
  10. Cox RA, García-Palmieri MR. Cholesterol, Triglycerides, and Associated Lipoproteins. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd.
  11. Dobiás̆ová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate inapob-lipoprotein-depleted plasma (FERHDL). Clin Biochem. 2001; 34(7): 583–588.
  12. Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, et al. Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease. Med J Islam Repub Iran. 2015; 29: 240.
  13. Wan Ke, Zhao J, Huang H, et al. The association between triglyceride/high-density lipoprotein cholesterol ratio and all-cause mortality in acute coronary syndrome after coronary revascularization. PLoS One. 2015; 10(4): e0123521.
  14. Lee MiJ, Park JT, Han SH, et al. The atherogenic index of plasma and the risk of mortality in incident dialysis patients: Results from a nationwide prospective cohort in Korea. PLoS One. 2017; 12(5): e0177499.
  15. Shimizu Y, Nakazato M, Sekita T, et al. Association of arterial stiffness and diabetes with triglycerides-to-HDL cholesterol ratio for Japanese men: the Nagasaki Islands Study. Atherosclerosis. 2013; 228(2): 491–495.
  16. McLaughlin T, Reaven G, Abbasi F, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol. 2005; 96(3): 399–404.
  17. Hermans MP, Ahn SA, Rousseau MF. log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males. Cardiovasc Diabetol. 2010; 9: 88.
  18. Onat A, Can G, Kaya H, et al. "Atherogenic index of plasma" (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. J Clin Lipidol. 2010; 4(2): 89–98.
  19. Hermans MP, Ahn SA, Rousseau MF. The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females. Lipids Health Dis. 2012; 11: 132.
  20. Kanthe PS, Patil BS, Bagali Sh, et al. Atherogenic Index as a Predictor of Cardiovascular Risk among Women with Different Grades of Obesity. IJCRIMPH. 2012; 4(10): 1767–1774.
  21. Flier JS. Biology of Obesity. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL. eds. Harrison’s Principles of Internal Medicine.17th ed. New York, NY : 462–464.
  22. Yildiz G, Duman A, Aydin H, et al. Evaluation of association between atherogenic index of plasma and intima-media thickness of the carotid artery for subclinic atherosclerosis in patients on maintenance hemodialysis. Hemodial Int. 2013; 17(3): 397–405.
  23. Ni W, Zhou Z, Liu T, et al. Gender-and lesion number-dependent difference in "atherogenic index of plasma" in Chinese people with coronary heart disease. Sci Rep. 2017; 7(1): 13207.
  24. Gritzenko O, Chumakova G, Veselovskaya N. Atherogenic indexes as predictors of stenotic complication after percutaneous coronary interventions or coronary artery bypass graft. Atherosclerosis. 2015; 241(1): e212.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl